Add like
Add dislike
Add to saved papers

Prognosis and management of corneal transplantation for herpetic keratitis.

One hundred thirty-two penetrating keratoplasties (91 patients) for herpetic keratoplasty were reviewed retrospectively. The overall survival rate of clear keratoplasties to two years was 64% and to five years was 62%. The significant prognostic factors were preoperative ocular inflammatory status and degree of corneal vascularization. The two-year survival rate of a clear keratoplasty was 69% where eyes were inflamed at the time of surgery, compared with 44% in actively inflamed eyes. Allograft rejection, the major cause of a clouded herpetic keratoplasty, increased in frequency with increasing corneal vascularization. Antiviral cover was not used with routine postoperative steroids or with steroid intensive therapy for rejection. Epithelial herpetic recurrences occurred in 32% of eyes undergoing allograft rejection within four months of initiation of treatment for rejection. This is compared with otherwise uncomplicated keratoplasties where the epithelial recurrence rate was 6% at four months, on high-dose postoperative corticosteroid therapy without antiviral cover.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

Related Resources

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app